PEPG Intrinsic Valuation and Fundamental Analysis - PepGen Inc

Watchlist Manager

Watchlist

Price: 2.7 USD -0.74% Market Closed

Market Cap: $186.8m

	PepGen Inc NASDAQ:PEPG	US
	Xchanging Solutions Ltd NSE:XCHANGING	IN

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value for PepGen Inc.

Do our valuations actually work? See backtest results .

Fundamental Analysis

What PepGen Does

Biotechnology Health Care

PepGen is a biotechnology company that develops drug candidates based on oligonucleotides, which are short strands of synthetic genetic material designed to influence how cells make proteins. Its lead programs aim to treat serious muscle and neuromuscular diseases, including conditions such as Duchenne muscular dystrophy and myotonic dystrophy, by helping cells produce healthier versions of the proteins they are missing or making incorrectly.

Headquarters: United States of America US
Employees: 56
IPO date: May 6, 2022

Read the full company overview

How PepGen makes money

Drug development

PepGen develops peptide-conjugated oligonucleotide medicines designed to treat genetic muscle and nerve diseases, especially Duchenne muscular dystrophy and myotonic dystrophy. The company runs research, testing, and clinical trials on these drug candidates.

Customers: Patients with rare genetic diseases, along with the doctors, hospitals, and trial sites that help test and eventually prescribe the medicines.
Revenue Model: It does not sell approved medicines yet. It mainly funds its work through research collaborations and other development funding, and it could later earn money from drug sales or licensing if a candidate is approved.

View Company Overview